Literature DB >> 745019

Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration.

G P Reynolds, P Riederer, M Sandler, K Jellinger, D Seemann.   

Abstract

Deprenyl is an inhibitor of monoamine oxidase type B, the enzyme responsible for 2-phenylethylamine oxidation, and is used in conjunction with L-Dopa therapy in Parkinson's disease. Post-mortem studies in human brain tissue have shown that after (-)deprenyl administration to parkinsonian patients amphetamine is present in concentrations up to 56 ng/g. It also could be shown that phenylethylamine concentrations are substantially increased in such patients. Phenylethylamine and amphetamine have been investigated using a gas chromatographic technique.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 745019     DOI： 10.1007/bf01246964

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  12 in total

1.  FORMATION OF BETA-PHENYLETHYLAMINE IN MAMMALIAN TISSUE AND ITS EFFECT ON MOTOR ACTIVITY IN THE MOUSE.

Authors:  T NAKAJIMA; Y KAKIMOTO; I SANO
Journal:  J Pharmacol Exp Ther       Date:  1964-03       Impact factor: 4.030

2.  Beta-phenylethylamine and locomotor activity in mice. Interaction with catecholaminergic neurones and receptors.

Authors:  D M Jackson
Journal:  Arzneimittelforschung       Date:  1975-04

3.  Phenylethylamine: evidence for a direct, postsynaptic dopamine-receptor stimulating action.

Authors:  S M Antelman; D J Edwards; M Lin
Journal:  Brain Res       Date:  1977-05-27       Impact factor: 3.252

4.  Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1973-11       Impact factor: 4.030

5.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

6.  The determination and distribution of 2-phenylethylamine in sheep brain.

Authors:  G P Reynolds; M Sandler; J Hardy; H Bradford
Journal:  J Neurochem       Date:  1980-05       Impact factor: 5.372

7.  Deprenyl is metabolized to methamphetamine and amphetamine in man.

Authors:  G P Reynolds; J D Elsworth; K Blau; M Sandler; A J Lees; G M Stern
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

8.  Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Authors:  J D Elsworth; V Glover; G P Reynolds; M Sandler; A J Lees; P Phuapradit; K M Shaw; G M Stern; P Kumar
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

Review 9.  The actions of amphetamine on neurotransmitters: a brief review.

Authors:  K E Moore
Journal:  Biol Psychiatry       Date:  1977-06       Impact factor: 13.382

10.  Deprenyl in Parkinson's disease.

Authors:  A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321
View more
  31 in total

1.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

Review 2.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

3.  Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

Authors:  M B Youdim; A Gross; J P Finberg
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  L-deprenyl plus L-phenylalanine in the treatment of depression.

Authors:  W Birkmayer; P Riederer; W Linauer; J Knoll
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

Review 5.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

6.  Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

Authors:  Zaid A Abassi; Ofer Binah; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

7.  Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.

Authors:  M K Lakshmana; B S Rao; N K Dhingra; R Ravikumar; S Sudha; B L Meti; T R Raju
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

Review 8.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

Review 9.  The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog.

Authors:  N W Milgram; G O Ivy; E Head; M P Murphy; P H Wu; W W Ruehl; P H Yu; D A Durden; B A Davis; I A Paterson
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

Review 10.  Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.

Authors:  M B Youdim; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.